96 related articles for article (PubMed ID: 29116071)
1. [CRISPR/Cas9-editing-based modeling of hypoxia in renal cancer cells].
Zhigalova NA; Zhenilo SV; Artemov AV; Prokhortchouk EB
Mol Biol (Mosk); 2017; 51(5):836-840. PubMed ID: 29116071
[TBL] [Abstract][Full Text] [Related]
2. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
3. VHL inactivation without hypoxia is sufficient to achieve genome hypermethylation.
Artemov AV; Zhigalova N; Zhenilo S; Mazur AM; Prokhortchouk EB
Sci Rep; 2018 Jul; 8(1):10667. PubMed ID: 30006568
[TBL] [Abstract][Full Text] [Related]
4. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
[TBL] [Abstract][Full Text] [Related]
6. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
Carroll VA; Ashcroft M
Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
[TBL] [Abstract][Full Text] [Related]
7. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
8. High nuclear expression of HIF1α, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
Basu M; Chatterjee A; Chakraborty B; Chatterjee E; Ghosh S; Samadder S; Pal DK; Roy A; Chakrabarti J; Ghosh A; Panda CK
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2309-2322. PubMed ID: 34080067
[TBL] [Abstract][Full Text] [Related]
9. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
10. NF-kappaB-dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas.
Pantuck AJ; An J; Liu H; Rettig MB
Cancer Res; 2010 Jan; 70(2):752-61. PubMed ID: 20068166
[TBL] [Abstract][Full Text] [Related]
11. von Hippel-Lindau exonic methylation analysis using MALDI-TOF mass spectrometry.
Lian F; Sreedharan S; Arnold RS; Master VA; Ogan K; Pattaras JG; Roberts DL; Petros JA
J Urol; 2014 Nov; 192(5):1528-33. PubMed ID: 24704013
[TBL] [Abstract][Full Text] [Related]
12.
Sun N; Petiwala S; Lu C; Hutti JE; Hu M; Hu M; Domanus MH; Mitra D; Addo SN; Miller CP; Chung N
CRISPR J; 2019 Aug; 2():230-245. PubMed ID: 31436504
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel hypoxia dependent and independent target genes of the von Hippel-Lindau (VHL) tumour suppressor by mRNA differential expression profiling.
Wykoff CC; Pugh CW; Maxwell PH; Harris AL; Ratcliffe PJ
Oncogene; 2000 Dec; 19(54):6297-305. PubMed ID: 11175344
[TBL] [Abstract][Full Text] [Related]
14. The VHL/HIF oxygen-sensing pathway and its relevance to kidney disease.
Haase VH
Kidney Int; 2006 Apr; 69(8):1302-7. PubMed ID: 16531988
[TBL] [Abstract][Full Text] [Related]
15. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis.
Serrano-Oviedo L; Giménez-Bachs JM; Nam-Cha SY; Cimas FJ; García-Cano J; Sánchez-Prieto R; Salinas-Sánchez AS
Urol Oncol; 2017 Mar; 35(3):114.e15-114.e22. PubMed ID: 27836247
[TBL] [Abstract][Full Text] [Related]
16. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
17. An IDH-independent mechanism of DNA hypermethylation upon VHL inactivation in cancer.
Artemov AV; Zhenilo S; Kaplun D; Starshin A; Sokolov A; Mazur AM; Szpotan J; Gawronski M; Modrzejewska M; Gackowski D; Prokhortchouk EB
Epigenetics; 2022 Aug; 17(8):894-905. PubMed ID: 34494499
[TBL] [Abstract][Full Text] [Related]
18. [Tumor suppressor gene VHL, hypoxia inducible factor, and renal cell carcinoma].
Zhang YT; Chen N; Zeng H; Zhou Q
Zhonghua Bing Li Xue Za Zhi; 2006 Sep; 35(9):562-4. PubMed ID: 17134554
[No Abstract] [Full Text] [Related]
19. Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism.
Leisz S; Schulz K; Erb S; Oefner P; Dettmer K; Mougiakakos D; Wang E; Marincola FM; Stehle F; Seliger B
Oncotarget; 2015 May; 6(13):11395-406. PubMed ID: 25890500
[TBL] [Abstract][Full Text] [Related]
20. HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase D.
Toschi A; Edelstein J; Rockwell P; Ohh M; Foster DA
Oncogene; 2008 Apr; 27(19):2746-53. PubMed ID: 17998935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
